A multicenter, double-blind study to determine the efficacy and safety of SYR-322 [alogliptin] plus pioglitazone HCl (Actos[Rm]), SYR-322 alone, or pioglitazone HCl alone in subjects with type 2 diabetes.

Trial Profile

A multicenter, double-blind study to determine the efficacy and safety of SYR-322 [alogliptin] plus pioglitazone HCl (Actos[Rm]), SYR-322 alone, or pioglitazone HCl alone in subjects with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Alogliptin (Primary) ; Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jun 2012 Pharmacodynamic results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 19 Aug 2010 Results published in Diabetes Care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top